CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
放疗作为 CD19 靶向 CAR-T 治疗桥接策略的疗效与安全性：系统综述与荟萃分析
英文原题：Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis.
查看英文原题
Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
放疗（RT）在大B细胞淋巴瘤中越来越多地被用作CD19靶向CAR-T 输注前的桥接治疗，但其临床作用仍不确定。我们开展了一项系统评价和meta分析，纳入16项研究，涉及488例接受桥接RT的大B细胞非霍奇金淋巴瘤患者。汇总估计显示，总体缓解率（ORR）为74.6%，完全缓解（CR）率为55%。1年无进展生存期（PFS）率和总生存期（OS）率分别为57.7%和72.1%。细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）分别发生于76.8%和36.9%的患者，其中3级事件分别为6.7%和19.1%。与全身性桥接治疗相比，RT与更优的生存相关，而结局与未桥接队列相当。这些发现提示，桥接RT在接受CAR-T 治疗的选择性患者中是一种可行、耐受良好且可能具有优势的策略。
展开英文摘要原文
Radiotherapy (RT) is increasingly used as bridging therapy before CD19-targeted CAR-T infusion in large B-cell lymphoma, but its clinical role remains uncertain.
We conducted a systematic review and meta-analysis of 16 studies involving 488 patients with large B-cell non-Hodgkin lymphoma who received bridging RT. Pooled estimates showed an overall response rate (ORR) of 74. 6% and complete response (CR) rate of 55%. The 1-year progression-free survival (PFS) and overall survival (OS) rates were 57. 7% and 72.
1%, respectively. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 76. 8% and 36. 9% of patients, with grade 3 events in 6. 7% and 19. 1%, respectively. Compared with systemic bridging, RT was associated with superior survival, while outcomes were comparable to non-bridging cohorts.
These findings suggest that bridging RT is a feasible, well-tolerated, and potentially advantageous in selected patients undergoing CAR-T therapy.
论文信息
- 作者
- Yu Y、Xiang Z、Hou X、Hu K、Zhang F
- 单位
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.China
- 文献类型
- 系统综述 · 荟萃分析
- 期刊
- Leukemia & lymphoma2026 Jan
- 原文标识
- PubMed 41195989 · DOI 10.1080/10428194.2025.2572420